Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

179
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
179
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

919
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
919
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction notice to "The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy" [Biomedicine & Pharmacotherapy 146 (2022) 112588].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Developmentally Inspired, Mechanical-Metabolic Dual Gradient Osteochondral Constructs Bridging Regeneration and Therapeutic Screening.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Bidirectional Mechanical Stimulation Enables Biomechanical Coupling and Functional Maturation in Arterial Microphysiological Systems.

Advanced healthcare materials·2026
Same author

Deep eutectic solvent-assisted chemosensing of Fe(iii), V(iii), C(ii), and P(ii) ions using a paper-based micro-array decorated by silver nanoparticles.

RSC advances·2025
Same author

Geometry-Guided Osteogenesis in Bone-on-a-Chip Systems Using Triply Periodic Minimal Surface Scaffolds.

Advanced healthcare materials·2025
Same author

Bioengineered Skin Grafts from Patient-Derived Decellularized Extracellular Matrix and Autologous Cells for Personalized Regenerative.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025

Related Experiment Video

Updated: Dec 12, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.7K

Thrombolytic Agents: Nanocarriers in Controlled Release.

Soodabeh Hassanpour1, Han-Jun Kim2,3, Arezoo Saadati4

  • 1Department of Analytical Chemistry, Faculty of Science, Palacky University Olomouc, 17. Listopadu 12, Olomouc, 77146, Czech Republic.

Small (Weinheim an Der Bergstrasse, Germany)
|August 14, 2020
PubMed
Summary

Nanocarriers improve thrombolytic agents (TAs) for dissolving blood clots by protecting them and targeting delivery. This enhances efficacy and reduces bleeding risks, paving the way for better clot-dissolving therapies.

Keywords:
drug deliverynanoparticlesplasminogen activatorsthrombolytic agentsthrombosis

More Related Videos

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
14:10

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

16.3K
Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

10.2K

Related Experiment Videos

Last Updated: Dec 12, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.7K
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
14:10

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

16.3K
Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

10.2K

Area of Science:

  • Biomedical Engineering
  • Pharmacology
  • Materials Science

Background:

  • Thrombosis involves blood clots obstructing blood flow, posing a significant health risk.
  • Thrombolytic agents (TAs) dissolve clots by converting plasminogen to plasmin, but systemic administration causes bleeding and protein-based TAs have short half-lives.

Purpose of the Study:

  • To review recent advances in thrombolytic agents (TAs) and nanocarrier technologies for targeted drug delivery.
  • To explore the potential of nanocarriers in overcoming limitations of traditional TAs and improving clinical outcomes.

Main Methods:

  • Review of current literature on thrombolytic agents and nanocarrier systems.
  • Analysis of various nanocarrier types (lipid-based, polymer-based, metal-based) for targeted TA delivery.
  • Discussion of challenges and future directions for TA development and clinical translation.

Main Results:

  • Nanocarriers enhance TA pharmacokinetics by protecting them from degradation and enabling targeted release.
  • Nanocarrier-based TAs demonstrate increased half-life, reduced side effects (e.g., bleeding), and improved overall efficacy.
  • Different nanocarrier platforms show promise for effective and safer thrombolytic therapy.

Conclusions:

  • Nanocarrier technology offers a promising strategy to improve the safety and efficacy of thrombolytic agents.
  • Targeted delivery systems are crucial for overcoming the limitations of conventional thrombolytic therapies.
  • Further research and clinical translation are needed to fully realize the potential of nanocarrier-based TAs.